Categories: News

Sensor Receives Conditional Approval

Toronto, Ontario–(Newsfile Corp. – November 30, 2023) – Sensor Technologies Corp. (CSE: SENS) (the “Company” or “Sensor”) is pleased to announce that, further to its press releases of June 30, 2023, the Company has received conditional approval from the Canadian Securities Exchange (“CSE”) with respect to the Company’s proposed change of business from a technology issuer to an investment issuer.

Final approval for the proposed change of business is conditional on the Company fulfilling the following conditions, among others:

  • the successful completion of the private placement for aggregate proceeds $500,000;

  • the completion of proposed debt conversions;

  • the completion of the Company’s investment in each of Robotic StemCell BioTech Ltd., Blockchain Assets Management Group Limited and 14125339 Canada Inc. (as described in the Company’s press release of January 19, 2023); and

  • the completion of any and all outstanding CSE application documentation and payment of applicable fees.

The Company intends to fulfill all of the conditions as soon as possible.

Corporation contact:

Philip Wong, Chief Executive Officer
email: ssphilipwong@gmail.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/189196

Staff

Recent Posts

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

1 hour ago

Hologic Announces Financial Results for First Quarter of Fiscal 2026

– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…

1 hour ago

Illumina completes acquisition of SomaLogic

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…

1 hour ago

RazorMetrics Drives More Than $11 Million in Prescription Drug Savings for Ohio Plans and Residents

AUSTIN, Texas, Jan. 30, 2026 /PRNewswire/ -- RazorMetrics, a leading innovator in pharmacy cost containment…

1 hour ago

NYSE Content Advisory: Pre-Market Update + Cast of HBO’s ‘Industry’ Rang Thursday’s Closing Bell

NEW YORK, Jan. 30, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a…

1 hour ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national…

1 hour ago